Clinical trial
Efficacy, Tolerance and Satisfaction With CLOBEX® Spray When Used as Monotherapy…
NCT00437216 · Galderma R&D, Industry · Completed
Key facts
| NCT number | NCT00437216 |
|---|---|
| Title | Efficacy, Tolerance and Satisfaction With CLOBEX® Spray When Used as Monotherapy or Add-on Therapy in Plaque Psoriasis |
| Official title | Phase 4 Open-Label Multicenter Community-based 4-Wk Trial to Assess Efficacy, Tolerance to Tx & Patient Satisfaction w/ CLOBEX® Spray When Used as Mono- or Add-on Therapy to Existing Systemic/Topical Agents for Tx of Plaque Psoriasis |
| Lead sponsor | Galderma R&D, Industry |
| Status | Completed |
| Study type | Observational |
| Conditions | Psoriasis |
| Intervention type | Drug |
| Interventions | Clobetasol Propionate, 0.05%, Clobetasol propionate, 0.05% Spray |
| Enrollment | 2,488 |
| Start date | Feb 1, 2006 |
| Primary completion | Jul 1, 2006 |
| Completion | Jul 1, 2006 |
| First posted | Feb 19, 2007 |
| Last update posted | Jul 29, 2022 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: